MIRA Pharmaceuticals, Inc. (MIRA)
Oxford Ledge is still expanding full research coverage of MIRA. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
MIRA Pharmaceuticals develops oral drug candidates for pain, neurological, metabolic, and addiction disorders through clinical and preclinical research.
SEC filings
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-07-10
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-07-06
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-06-25
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-06-17
- 8-K Departure/election of directors or officers; Financial statements and exhibits 2026-06-08
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for MIRA. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open MIRA in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.